Pharmacoepidemiology of antipsychotic use in youth with ADHD: Trends and clinical implications

Current Psychiatry Reports

Volumn 15, Issue 8, 2013, Pages

  Birnbaum, Michael L ^a   Saito, Ema ^a,b   Gerhard, Tobias ^c,d   Winterstein, Almut ^e   Olfson, Mark ^f   Kane, John M ^a,b,g,h   Correll, Christoph U ^a,b,g,h  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f Feinstein Institute for Medical Research ^*  (United States)

^g FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

ADHD; Antipsychotics; Attention deficit hyperactivity disorder; Correlates; Pharmacoepidemiology; Prescribing; Psychiatry; Trends

Indexed keywords

ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CLONIDINE; NEUROLEPTIC AGENT;

ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; COMORBIDITY; CROSS-SECTIONAL STUDY; DEPRESSION; DISRUPTIVE BEHAVIOR; DRUG USE; HUMAN; LONGITUDINAL STUDY; MENTAL DEFICIENCY; PEDIATRICS; PHARMACOEPIDEMIOLOGY; PREVALENCE; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; CHILD; PRESCHOOL CHILD; PRESCRIPTION; REVIEW; STATISTICS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; HUMANS; PHARMACOEPIDEMIOLOGY; YOUNG ADULT;

EID: 84882400986     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0382-3     Document Type: Article

References (46)

1. •• Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247-56. This article demonstrates the significant increase in antipsychotic prescriptions in youth in the US in both youth and adults and explores the various characteristics associated with antipsychotic prescriptions.
2. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-84.
3. •• Matone M, Localio R, Huang YS, dosReis S, Feudtner C, Rubin D. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children. Health Serv Res. 2012;47(5):1836-60. This article highlights the growing trend towards antipsychotic prescription in US youth, in particular for non-approved indications.
4. Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, et al. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry. 2012;69(4):372-80.
5. Costello EJ, Copeland W, Angold A. Trends in psychopathology across the adolescent years: what changes when children become adolescents, and when adolescents become adults? J Child Psychol Psychiatry. 2011;52(10):1015-25.
6. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry. 2011;72(5):655-70.
7. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. A rational, evidence informed approach to psychopharmacology for adolescents with early onset, first episode psychoses. Curr Opin Psychiatry. 2013;26(2):219-30.
8. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9-20.
9. Pathak P, West D, Martin BC, Helm ME, Henderson C. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123-9.
10. •• Zito JM, Burcu M, Ibe A, Safer DJ, Magder LS. Antipsychotic use by Medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade. Psychiatr Serv. 2013;64(3):223-9. This article demonstrates the significant increase in antipsychotic use for Medicaid enrolled youth with ADHD between 1997 and 2006. It highlights the different prescription patterns for youth based on socio-economic factors as opposed to diagnostic characteristics.
11. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629-35.
12. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-73.
13. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114-26.
14. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144-58.
15. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517-35.
16. Alessi-Severini S, Biscontri RG, Collins DM, Sareen J, Enns MW. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry. 2012;57(1):52-8.
17. Classi PM, Le TK, Ward S, Johnston J. Patient characteristics, comorbidities, and medication use for children with ADHD with and without a co-occurring reading disorder: A retrospective cohort study. Child Adolesc Psychiatry Ment Health. 2011;5:38.
18. Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther. 2010;32(5):949-59.
19. • Constantine RJ, Jentz S, Bengtson M, McPherson M, Andel R, Jones MB. Exposure to antipsychotic medications over a 4-year period among children who initiated antipsychotic treatment before their sixth birthday. Pharmacoepidemiol Drug Saf. 2012;21(2):152-60. This article highlights the concerning trend towards antipsychotic medication use in very young children and the urgent need to better understand their long-term effects.
20. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158(8):753-9. (Pubitemid 39025073)
21. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770-81.
22. Dosreis S, Yoon Y, Rubin DM, Riddle MA, Noll E, Rothbard A. Antipsychotic treatment among youth in foster care. Pediatrics. 2011;128(6):e1459-66.
23. Fullerton CA, Epstein AM, Frank RG, Normand SL, Fu CX, McGuire TG. Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005. Psychiatr Serv. 2012;63(2):115-21.
24. • Garfield CF, Dorsey ER, Zhu S, Huskamp HA, Conti R, Dusetzina SB, et al. Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010. Acad Pediatr. 2012;12(2):110-6. This article demonstrated the large increase in ADHD diagnosis in the US between 2000 and 2010 as well as the provider shift from pediatricians to psychiatrists.
25. Goodwin R, Gould MS, Blanco C, Olfson M. Prescription of psychotropic medications to youths in office-based practice. Psychiatr Serv. 2001;52(8):1081-7. (Pubitemid 32758001)
26. Halloran DR, Swindle J, Takemoto SK, Schnitzler MA. Multiple psychiatric diagnoses common in privately insured children on atypical antipsychotics. Clin Pediatr (Phila). 2010;49(5):485-90.
27. Hodgkins P, Sasané R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther. 2011;33(2):188-203.
28. • Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13-23. This article highlights the concerning trend towards antipsychotic medication use in very young children and the urgent need to better understand factors explaining this trend.
29. Patel NC, Crismon ML, Shafer A. Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother. 2006;40(2):205-11. (Pubitemid 43269848)
30. Pringsheim T, Lam D, Patten SB. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009. J Child Adolesc Psychopharmacol. 2011;21(6):537-43.
31. Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA. Psychotherapeutic medication patterns for youths with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 1999;153(12):1257-63.
32. Zito JM, Safer DJ, Sai D, Gardner JF, Thomas D, Coombes P, et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008;121(1):e157-63.
33. Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics. 2007;119 Suppl 1:S99-106. (Pubitemid 46397953)
34. Kessler RC, Avenevoli S, Costello J, Green JG, Gruber MJ, McLaughlin KA, et al. Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry. 2012;69(4):381-9.
35. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-91.
36. •• Knapp P, Chait A, Pappadopulos E, Crystal S, Jensen PS, on behalf of the T-MAY Steering Group. Treatment of Maladaptive Aggression in Youth: CERT Guidelines I. Engagement, Assessment, and Management. Pediatrics. 2012;129(6):e1562-76. This is the first of a two-set article series on the management of maladaptive aggression in youth, focusing on the evidence-based engagement, assessment and non-pharmacologic management of pediatric aggression that is a frequently cited reason for antipsychotic use in youth with ADHD.
37. •• Scotto Rosato N, Correll CU, Pappadopulos E, Chait A, Crystal S. Jensen PS; on behalf of the Treatment of Maladaptive Aggressive in Youth Steering Committee. Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. Treatments and Ongoing Management. Pediatrics. 2012;129(6):e1577-86. This is the second of a two-set article series on the management of maladaptive aggression in youth, focusing on the evidence-based psychotherapeutic and psychopharmacologic management of pediatric aggression that is a frequently cited reason for antipsychotic use in youth with ADHD.
38. Turgay A. Psychopharmacological treatment of oppositional defiant disorder. CNS Drugs. 2009;23(1):1-17.
39. Nevels RM, Dehon EE, Alexander K, Gontkovsky ST. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol. 2010;18(2):184-201.
40. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007;16(2):104-20. (Pubitemid 46643895)
41. Pappadopulos E, Rosato NS, Correll CU, Findling RL, Lucas J, Crystal S, et al. Experts' recommendations for treating maladaptive aggression in youth. J Child Adolesc Psychopharmacol. 2011;21(6):505-15.
42. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(6):642-57. (Pubitemid 43833097)
43. Blader JC, Pliszka SR, Jensen PS, Schooler NR, Kafantaris V. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. Pediatrics. 2010;126(4):e796-806.
44. Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol. 2009;19(4):403-14.
45. Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med. 2010;164(4):344-51.
46. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline Concordant Monitoring of Metabolic Risk in People with Mental Ill Health: Systematic Review and Meta-Analysis of Screening Practices. Psychol Med. 2012;42(1):125-47.